PILA PHARMA Advances to Clinical Obesity Trials Despite Inconclusive Preclinical Results
核心洞察
PILA PHARMA (搜索) has signed with a new clinical CRO to prepare a clinical trial application for XEN-D0501 in obesity (搜索), expected to be submitted by the end of Q1 2026.
Two completed rat obesity (搜索) studies showed no effect on body weight, but results remain inconclusive pending exposure analyses to determine if rats actually absorbed the compound.
The company used an untested formulation for the preclinical studies due to tolerability issues with their standard formulation in obese rats, potentially compromising drug absorption.
PILA PHARMA (搜索) AB has entered into an agreement with a new clinical Contract Research Organisation (CRO) to advance its TRPV1 (搜索) inhibitor XEN-D0501 into clinical testing for obesity (搜索), despite inconclusive results from recently completed preclinical studies. The Swedish biotech company announced that the clinical trial application is intended to be submitted around the end of Q1 2026.
Preclinical Studies Show Mixed Results
The company completed two 28-day obesity (搜索) studies in diet-induced obese (DIO) rats and Zucker rats according to protocol, but preliminary results showed that body weight and other reported endpoints were not affected in rats intended to be treated with XEN-D0501. However, the results remain inconclusive as crucial exposure analyses are still pending.
The uncertainty stems from a formulation challenge that emerged just before the studies began. PILA PHARMA (搜索)'s own formulation for preclinical oral delivery, which was well tolerated in 13-week toxicology studies, was not tolerated by obese rats. Rather than cancel the studies after already committing time and funds, the company opted to use an alternative aqueous solution formulation that had never previously been tested with XEN-D0501.
"The risk of using the new formulation, however, could be that XEN-D0501 absorption and thus resulting blood levels/exposure would be compromised, i.e. lower than expected and needed for efficacy," the company stated.
Management Confident in Clinical Progression
Despite the inconclusive preclinical data, PILA PHARMA (搜索)'s leadership expressed confidence in moving forward with clinical testing. Founder and CSO Dorte X. Gram commented: "I'm pleased that we're now moving back to clinical testing of XEN-D0501 where we know we have good exposure of XEN-D0501 with the current tablet formulation."
CEO Gustav H. Gram noted that the company's successful fundraise last summer, which was oversubscribed by 293.5%, provided additional funds to accelerate the dose-finding study in people living with obesity (搜索).
XEN-D0501's Clinical Track Record
XEN-D0501 is a selective, synthetic small molecule TRPV1 (搜索) inhibitor that has already demonstrated safety and tolerability in clinical testing. The company has completed two phase 2a clinical trials (PP-CT01 and PP-CT02) that showed XEN-D0501 is well tolerated in people living with obesity (搜索) and type 2 diabetes (搜索).
In the PP-CT02 trial, XEN-D0501 administered as 4 mg twice daily for 28 days demonstrated statistically significant enhancement of endogenous insulin response to oral glucose versus placebo. The treatment also resulted in a highly statistically significant reduction in ANP, a cardiovascular biomarker for heart failure.
Addressing the Obesity Pandemic
The development comes as obesity (搜索) reaches pandemic proportions, with estimates of more than 1 billion people living with obesity in 2025 and 4 billion people globally classified as overweight. Recent advances in anti-obesity drugs have proven that pharmacological weight management can provide quality-of-life and longevity benefits, sparking interest in potential oral treatments that can meet accessibility criteria for the enormous and growing demand.
PILA PHARMA (搜索)'s approach targets TRPV1 (搜索) inhibition, which down-regulates neurogenic inflammation and has demonstrated applications across pain and inflammatory diseases. The principle of treating diabetes and obesity (搜索) with TRPV1 inhibitors was discovered by founder Dorte X. Gram during her PhD studies at Novo Nordisk, where she found that TRPV1 inhibitors prevented glucose intolerance and body weight gain in spontaneously obese pre-diabetic rats.